Literature DB >> 329

Pneumococcal type-associated variability in alternate complement pathway activation.

D P Fine.   

Abstract

Opsonization of Streptococcus pneumoniae may be mediated by the alternate complement pathway. To study the importance of this interaction to human disease, complement consumption by pneumococci of various serotypes was measured in humwn serum chelated with ethyleneglycoltraacetic acid, a substance that blocks the classic but not the alternate complement pathwway. Serotype I, in contrast to all other types studied, lacked ability to consume complement in this system. The ability for serotypes III, IV, and VIII to activate the alternate pathway could be eliminated by prior serum absorption at O C with they type in question, a condition that would remove antibody but not complement. Types VII, XII, XIV, and XXV readily activated the alternate pathway in unabsorbed and absorbed sera. Differences could not be related to properties of the capsules. It was concluded that types I, III, IV, and VIII lack intrinsic ability to activate and thus be opsonized by the alternate complement pathway, although types III, IV, and VIII can do so in concert with specific antibody. The fact that these same types are especially prominent in human disease suggests that the ability to evade opsonization by the alternate complement pathway in pre-antibody phases of infection may be a virulence factor in pneumococci.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 329      PMCID: PMC415355          DOI: 10.1128/iai.12.4.772-778.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.

Authors:  R AUSTRIAN; J GOLD
Journal:  Ann Intern Med       Date:  1964-05       Impact factor: 25.391

2.  Types of pneumococci found in blood, spinal fluid and pleural exudate during a period of 15 years (1954-1969).

Authors:  E Lund
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1970

3.  The C3-activator system: an alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

4.  Sensitization of E. coli to the serum bactericidal system and to lysozyme by ethyleneglycoltetraacetic acid.

Authors:  C S Bryan
Journal:  Proc Soc Exp Biol Med       Date:  1974-04

Review 5.  Opsonins: their function, identity, and clinical significance.

Authors:  J A Winkelstein
Journal:  J Pediatr       Date:  1973-05       Impact factor: 4.406

6.  Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era.

Authors:  M A Mufson; D M Kruss; R E Wasil; W I Metzger
Journal:  Arch Intern Med       Date:  1974-09

7.  The role of immunoglobulin in the interaction of pneumococci and the properdin pathway: evidence for its specificity and lack of requirement for the Fc portion of the molecule.

Authors:  J A Winkelstein; H S Shin
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

8.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

9.  Influence of the alternate complement pathway in opsonization of several bacterial species.

Authors:  A Forsgren; P G Quie
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

10.  Microbial persistence.

Authors:  W McDERMOTT
Journal:  Yale J Biol Med       Date:  1958-02
View more
  44 in total

1.  Alternate complement pathway activation by group A streptococci: role of M-protein.

Authors:  A L Bisno
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

2.  Lung bacterial clearance in murine pneumococcal pneumonia.

Authors:  M J Ansfield; D E Woods; W G Johanson
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

3.  Role of antibody and complement in opsonization of group B streptococci.

Authors:  A O Shigeoka; R T Hall; V G Hemming; C D Allred; H R Hill
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

4.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

5.  Lymphocyte subset populations in children with polysaccharide antibody deficiency following cardiac transplantation.

Authors:  A R Gennery; D Barge; G P Spickett; A J Cant
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

6.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Enzyme immunoassay for detection of pneumococcal antigen in cerebrospinal fluid.

Authors:  R H Yolken; D Davis; J Winkelstein; H Russell; J E Sippel
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

8.  Alterations in serum opsonic activity and complement levels in pneumococcal disease.

Authors:  G S Giebink; T H Dee; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

9.  An association between homozygous C3 deficiency and low levels of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  M A Hazlewood; D S Kumararatne; A D Webster; M Goodall; P Bird; M Daha
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

10.  Neutrophil function in gram-negative rod bacteremia. The interaction between phagocytic cells, infecting organisms, and humoral factors.

Authors:  R J Weinstein; L S Young
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.